Biotechnology

Lakewood-Amedex Biotherapeutics

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

Maxlinear

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Scinai Immunotherapeutics

TAVIA ACQUISITION CORP COM USD0.0001 (SUBS/RIGHTS)

Direxion Daily INTC Bull 2X ETF

GraniteShares 2x Long INTC Daily ETF

Atomera

eLong Power

iHeartMedia

Tradr 2X Long AAOI Daily ETF

LABT

<p>Lakewood - Amedisys (LABT.US) current price $8.34, down 3.58% for the day, with a rapid decline accelerating within 5 minutes. As a small-cap company in the biopharmaceutical sector, LABT has not disclosed any significant announcements recently. This rapid intraday drop may be related to fluctuations in short-term capital sentiment and weak liquidity. The market is paying attention to changes in trading volume and whether there will be any follow-up fundamental news</p>

涛哥小摩托

Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics Drops Over 3% Intraday

Lakewood-Amedex Biotherapeutics(LABT.US)

Lakewood-Amedex Biotherapeutics Stock Performance Chart

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

Lakewood-Amedex Biotherapeutics Drops Over 3% Intraday